Key Highlights
- India’s PRIP Scheme allocates ₹5000 crore (2023-2028) to transition pharma from cost-based generics to innovation-driven growth
- Seven Centres of Excellence established at NIPERs focusing on anti-viral drugs, medical devices, biosimilars, and novel drug delivery systems
- Supports ~300 innovation projects with total R&D investment of ₹11,000 crore in new chemical entities, biologics, gene therapy, and AI-powered MedTech
- Strategic focus on orphan drugs, antimicrobial resistance, and precision medicines addressing India’s unmet healthcare needs
- Industry-academia collaboration incentivized with up to 50% funding support for early-stage projects and 35% for later-stage innovations
India at the Crossroads of Pharmaceutical Evolution
India has long worn the crown of the “Pharmacy of the World”—a title earned through decades of supplying 20% of global generic drugs and 60% of the world’s vaccines. From meeting 40% of US generic demand to providing 25% of all medicines in the UK, India’s pharmaceutical prowess in affordable healthcare is unmatched. With over 10,000 manufacturing facilities and 670 USFDA-approved plants (the highest outside the US), the nation has established itself as a volume giant in the global pharmaceutical landscape. investindia.gov
However, beneath this impressive facade lies a critical challenge. While India excels in cost-competitive generics production, it significantly lags behind global peers in innovation, R&D intensity, and cutting-edge pharmaceutical research. Indian pharma companies invest merely 5-8% of revenues in R&D compared to 15-20% by US firms and 18-22% by European giants. Global firms outperform Indian counterparts by 3.0x in R&D intensity and generate 5.6 times more patents per billion USD revenue.
This innovation deficit poses existential risks as the global pharmaceutical industry pivots toward biologics, biosimilars, precision medicine, gene therapy, and AI-driven drug discovery. Countries like China, Brazil, and South Korea are rapidly scaling their innovation capacities, threatening India’s traditional generics dominance.
Enter the Promotion of Research & Innovation in Pharma MedTech Sector (PRIP) Scheme—notified in August 2023 with a groundbreaking ₹5000 crore outlay over five years (2023-2028). This transformative initiative represents India’s most ambitious attempt to reposition itself from a volume-based generics supplier to a value-driven innovation powerhouse capable of competing in high-value pharmaceutical segments globally.
India’s Pharmaceutical Strengths: The Foundation for Transformation
Unparalleled Global Market Position
India’s pharmaceutical sector contributes 1.72% to national GDP and stands as the world’s third-largest by volume and 13th by value. The industry’s $50-55 billion valuation (FY 2023-24) is projected to reach $120-130 billion by 2030, potentially doubling its GDP contribution.
The country manufactures 60,000 generic brands across 60 therapeutic categories, supplying medicines to over 200 countries. India’s vaccine manufacturing capacity is particularly formidable—producing 40-70% of WHO’s demand for DPT and BCG vaccines and 90% of measles vaccine requirements.
Cost-Competitive Manufacturing Excellence
India’s competitive advantage stems from its world-class manufacturing infrastructure combined with a skilled, cost-effective workforce. With a talent pool graduating thousands of science and engineering professionals annually, the nation maintains 3,000+ pharma companies and over 500 active pharmaceutical ingredient (API) manufacturers contributing 8% to global API production.
The cost arbitrage enables Indian manufacturers to produce high-quality medicines at 30-40% lower costs than Western counterparts, making treatments accessible to millions in developing nations.
The Innovation Gap: Confronting India’s R&D Crisis
Low R&D Intensity and Patent Output
Despite its manufacturing prowess, India’s pharmaceutical innovation metrics reveal a troubling picture. Research intensity averages a mere 0.7% of GDP in healthcare compared to 2.5-3% in developed economies. Indian firms allocate less than 2% of revenue to R&D against the global pharmaceutical industry standard of 15%+. knnindia.co
This underinvestment manifests in stark innovation output gaps. Global pharmaceutical companies generate 8.4 times more publications and 5.6 times more patents per billion USD revenue than Indian firms. Only four Indian companies rank among the top performers for patents by revenue, with Dr. Reddy’s Laboratories leading domestic firms at 10.3% R&D intensity.
NIPERs—India’s premier pharmaceutical research institutes—have collectively filed only 425 patents and published 8,048 research papers since inception, a fraction of output from comparable international institutions.
Regulatory Barriers and Infrastructure Gaps
The innovation ecosystem faces multiple structural challenges. India’s patent law tensions between access-to-medicines principles and innovator incentives create uncertainty for R&D investments. The revised Schedule M GMP compliance requirements—aligning India with WHO standards—demand significant infrastructure upgrades, particularly challenging for 8,500+ small and medium pharmaceutical units granted extensions until December 2025.
Regulatory approval processes for new drugs remain slower than global benchmarks, and weak IP enforcement historically discouraged proprietary innovation.
Competition from Emerging Pharma Powers
China has emerged as a formidable competitor, with firms now spending 8-10% of revenues on R&D backed by massive state-funded innovation programs. Chinese pharmaceutical patents have proliferated across biotechnology, AI, and biologics. Brazil and South Korea similarly accelerated innovation capacities through strategic government interventions.
India risks missing the biotechnology wave unless it rapidly scales innovation capabilities.
PRIP Scheme: Architecture of India’s Innovation Transformation
Vision and Strategic Objectives
The PRIP Scheme embodies a fundamental strategic pivot—transforming Indian pharma from cost-based competitiveness to innovation-based growth. Core objectives include:
- Strengthening R&D infrastructure through world-class research facilities
- Promoting industry-academia linkages for translational research
- Nurturing a culture of quality research and retaining scientific talent
- Building sustained global competitive advantage in high-value pharmaceutical segments
- Encouraging innovation for human and animal health with focus on unmet medical needs
Governance Framework: Multi-Stakeholder Oversight
An Empowered Committee chaired by the CEO of NITI Aayog provides strategic guidance, comprising secretaries from:
- Department of Pharmaceuticals
- Ministry of Health & Family Welfare
- Indian Council of Medical Research (ICMR)
- Department of Biotechnology (DBT)
- Council of Scientific and Industrial Research (CSIR)
- AYUSH and Department of Science & Technology (DST)
This multi-ministerial structure ensures alignment across government, academia, and industry stakeholders.
Component A: Centres of Excellence at NIPERs
Infrastructure Investment
Component A allocates ₹700 crore over five years to establish seven Centres of Excellence (CoEs), one at each existing NIPER. As of 2024, these CoEs have approved 104 research projects and filed 2 patents, with ongoing infrastructure development. pib.gov
Strategic Specializations Across Seven NIPERs
Each CoE focuses on distinct high-priority research domains:
These specializations address critical gaps—from antimicrobial resistance (AMR) drug development to affordable medical devices and biosimilar production.
Accelerating Industry-Academia Knowledge Transfer
CoEs serve as bridges between academic research and commercial applications. NIPER Raebareli’s NDDS Centre aims to overcome limitations of existing drug delivery systems through consultancy, contract research, and industry collaboration to translate research to market. Similar initiatives at other NIPERs include 303+ MOUs with industries and academic institutions.
Component B: Priority Research Funding for Innovation Projects
₹4,250 Crore for Breakthrough Research
Component B allocates ₹4,250 crore to support industry and startup-led R&D in collaboration with academic institutions. The scheme targets ~300 innovation projects catalyzing ₹11,000 crore total R&D investment. PRIPscheme
Six Strategic Priority Research Areas
Funding focuses on six transformative domains:
1. New Chemical Entities (NCEs): Including biologics, biosimilars, and phytopharmaceuticals—addressing India’s negligible contribution to novel drug discovery
2. Complex Generics and Biosimilars: Leveraging India’s manufacturing expertise to capture high-value segments as blockbuster biologics approach patent cliffs (Opdivo 2028, Keytruda 2028)
3. Precision Medicines: Gene therapy, stem cell technologies, and personalized treatments—domains requiring cutting-edge capabilities
4. AI/ML-Powered Medical Devices: Next-generation diagnostics and therapeutics utilizing artificial intelligence and machine learning
5. Orphan Drugs for Rare Diseases: Addressing 72-96 million Indians affected by 450+ rare diseases with limited treatment options
6. Antimicrobial Resistance (AMR): Critical global health priority where India faces 600,000 annual deaths from resistant infections
Tiered Financial Support Structure
The amended scheme (September 2024) provides differentiated funding:
Early-Stage Projects (up to ₹9 crore):
- 100% assistance for costs up to ₹1 crore
- 50% assistance for additional costs beyond ₹1 crore
- Maximum support: ₹5 crore
Later-Stage Projects (up to ₹285 crore):
Strategic Priority Innovation (SPI) Areas:
For orphan drugs, AMR, vaccine-preventable diseases, vector-borne diseases, and pandemic pathogens:
Industry-Academia Collaboration Incentives
The scheme prioritizes partnerships between industry/startups and reputed academic/government research institutions. Up to nine projects each at early and later stages receive selection preference for strong collaborative development. Firms may in-license research outputs from academic institutions using scheme funds, creating viable pathways from lab to market.
Enabling Ecosystem: Patent Mitra and MedTech Mitra
Medical Innovations Patent Mitra
Launched by ICMR in March 2025, Patent Mitra provides end-to-end patent filing support to biomedical innovators. The initiative offers:
- Patentability assessments and strategic IP guidance
- Patent filing, prosecution, and maintenance support
- Technology transfer facilitation to industry partners
At the India MedTech Expo 2025, ICMR licensed nine cutting-edge technologies under Patent Mitra, resulting in 17 licensing deals for infectious disease diagnostics, immunodiagnostics, and vaccines.
MedTech Mitra: Accelerating Medical Device Innovation
MedTech Mitra supports startups and industry in developing regulation-compliant Indian MedTech products. The platform provides regulatory navigation, testing support, and market access guidance—critical for scaling indigenous medical devices.
Pan-India Digital Innovation Exchange
PRIP envisions a digital Pharma-MedTech innovation exchange connecting innovators with:
- Investors and venture capital
- Mentors and industry experts
- Government initiatives (Patent Mitra, MedTech Mitra)
- Global collaboration opportunities
This ecosystem approach ensures comprehensive support from idea to market.
Expected Impact: Transforming India’s Pharmaceutical Landscape
For Industry: De-Risking Innovation
PRIP financially de-risks costly, long-term R&D, making innovation feasible for MSMEs and startups. By offsetting 35-50% of project costs, the scheme enables smaller firms to compete in biologics, biosimilars, and novel therapeutics—segments previously dominated by multinational corporations.
The initiative creates a robust innovation pipeline for original drugs, complex generics, and medical devices, potentially generating thousands of high-skill jobs.
For Academia: World-Class Research Infrastructure
NIPERs gain state-of-the-art facilities rivaling international institutions. Upgraded infrastructure attracts top talent, including overseas researchers returning to India, while collaborative funding opportunities encourage publication of high-impact research.
NIPER graduates—currently 10,960 alumni—provide a skilled workforce to industry and R&D organizations.
For India’s Global Standing: Value-Chain Ascension
PRIP positions India to move up the pharmaceutical value chain—from generics supplier to drug innovator and MedTech hub. Success in biosimilars (where India already has 95+ CDSCO-approved products) and entry into precision medicine could significantly enhance export value beyond current $25.3 billion (FY 2022-23).
Enhanced global reputation attracts foreign investment and strengthens India’s role in international health security frameworks—from G20 health priorities to WHO global health initiatives.
For Society: Affordable Innovation for Unmet Needs
PRIP directs innovation toward critical public health priorities:
- Rare diseases affecting 72-96 million Indians with limited treatment access
- Antimicrobial resistance—a crisis claiming 600,000 Indian lives annually
- Affordable medical devices for rural and underserved populations
- Vaccine development for pandemic preparedness
By incentivizing orphan drug development and AMR-focused research, PRIP ensures innovations serve both commercial viability and societal impact.
Challenges and Critical Success Factors
Intellectual Property and Regulatory Harmonization
India’s patent regime must balance access-to-medicines principles with sufficient innovator incentives. Streamlining patent processes and providing fast-track reviews for PRIP-supported innovations will accelerate commercialization.
The Schedule M revision—bringing GMP standards to WHO-PIC/S levels—demands significant compliance investments, particularly for 8,500 SME units. Sustained financial and technical support is essential to prevent quality gaps.
Sustained Funding and Project Selection
Ensuring transparent, merit-based project selection and timely fund disbursement will determine PRIP’s credibility. Realistic assessment of commercial viability and public health impact should guide funding decisions.
India’s historically low R&D spend (<2% of pharma revenue) requires cultural transformation. Industry must commit matching investments beyond government support.
Global Competition and Talent Retention
China’s 8-10% R&D intensity and massive state-backed innovation funds set aggressive benchmarks. Brazil and South Korea similarly accelerate pharmaceutical capabilities.
India must attract and retain global talent, preventing brain drain while encouraging diaspora researchers to return. Competitive salaries, world-class facilities, and intellectual freedom are prerequisites.
Industry-Academia Collaboration Quality
While PRIP incentivizes partnerships, meaningful collaboration requires cultural shifts. Industry must move beyond transactional relationships to genuine co-development models. Academic institutions need flexibility in IP sharing and commercialization processes.
The NIPER Academia-Industry Coordination Committee aims to institutionalize linkages, but success depends on sustained engagement.
Global Comparative Perspective
US and Europe: Deep IP Protection and R&D Investment
Western pharmaceutical giants invest 15-22% of revenues in R&D, protected by robust IP regimes and fast regulatory approvals. Pfizer, Roche, and Novartis maintain multi-billion dollar research budgets, filing hundreds of patents annually.
Academia-industry partnerships are deeply embedded—US universities generate significant licensing revenues from pharmaceutical innovations.
China: State-Backed Innovation Juggernaut
China’s pharmaceutical innovation acceleration stems from massive government funding, integrated manufacturing-research complexes, and rapid regulatory reforms. Chinese firms now spend 8-10% of revenues on R&D—double India’s average—with strong focus on biologics, AI-driven drug discovery, and biosimilars.
China’s patent filings in biotechnology and precision medicine have surged, positioning the nation as a formidable innovation competitor.
India’s Hybrid Model: Leveraging Cost Advantage
PRIP attempts a balanced approach—building on India’s cost-competitive manufacturing while investing strategically in high-value innovation. Unlike China’s top-down state control, India emphasizes public-private partnerships and decentralized innovation ecosystems.
Success requires sustained political will, regulatory consistency, and industry commitment matching global benchmarks.
Policy Roadmap: Actionable Recommendations
1. Holistic Regulatory Reform
- Fast-track approval processes for PRIP-supported innovations, reducing time-to-market
- Harmonize domestic GMP standards with WHO-PIC/S globally, ensuring export competitiveness
- Establish dedicated regulatory pathways for orphan drugs, biosimilars, and precision medicines
2. IPR Ecosystem Strengthening
- Simplify patent filing and reduce costs for startups and MSMEs
- Incentivize IP creation through tax benefits and grant preferences
- Leverage Patent Mitra for comprehensive IP support across biomedical innovations
3. Deepening Industry-Academia Linkages
- Establish regional technology transfer cells at all NIPERs for commercializing academic inventions
- Host innovation hackathons and challenge funds modeled on global best practices
- Create flexible IP-sharing frameworks balancing academic freedom and commercial returns
4. Infrastructure and Sustained Funding
- Ensure transparent PRIP fund disbursement with clear milestones and accountability
- Foster MedTech hubs at all NIPERs, integrating device innovation with pharmaceutical research
- Support MSMEs through soft loans, technical training, and regulatory compliance assistance
5. Global Collaboration and Market Access
- Enter co-development agreements with EU/US/Japan pharma for joint research on global health priorities
- Leverage G20 and WHO channels for collaborative vaccine and diagnostics development
- Participate in international clinical trials to validate Indian innovations globally
6. MSME Capacity Building
- Provide GMP compliance training and infrastructure grants for Schedule M adherence
- Create MSME consortia for joint R&D and product development, pooling resources
- Facilitate access to advanced testing facilities and analytical equipment at NIPERs
7. Ethical Innovation and Social Responsibility
- Mandate orphan drug development and AMR-focused research as key PRIP performance metrics
- Prioritize affordable innovation addressing India’s disease burden (TB, malaria, NCDs)
- Ensure equitable access mechanisms for therapies developed with public funding
Conclusion: A Defining Moment for Indian Pharma
The PRIP Scheme represents a watershed moment in India’s pharmaceutical journey—a deliberate, strategic pivot from volume-based generics dominance to value-driven innovation leadership. With its ₹5000 crore outlay, dual focus on research infrastructure (CoEs) and priority R&D funding, and comprehensive ecosystem support through Patent Mitra and MedTech Mitra, PRIP provides the architecture for transformative change.
However, implementation will determine destiny. India must navigate complex IPR challenges, ensure sustained funding and transparent governance, foster genuine industry-academia collaboration, and compete against aggressive global peers like China and Brazil. The Schedule M compliance deadline tests the sector’s quality commitment, while rare disease and AMR focus reflects social responsibility imperatives.
Success will require political consistency, industry investment matching government support, academic entrepreneurialism, and regulatory agility. If executed effectively, PRIP can help India achieve twin goals—maintaining its generics legacy (critical for global affordable healthcare) while becoming a true innovation powerhouse in biologics, precision medicine, and next-generation therapeutics.
As Dr. Mansukh Mandaviya stated at PRIP’s launch, “This is an inflection point in the journey of Atmanirbharta in pharma and medical devices”. The coming years will reveal whether India can leverage its manufacturing prowess, scientific talent, and innovation ecosystem investments to ascend the global pharmaceutical value chain—transforming from the “Pharmacy of the World” to the “Innovation Lab of the World.”
+ There are no comments
Add yours